This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

BLI801 Laxative in Constipated Adults

This study has been completed.
Information provided by (Responsible Party):
Braintree Laboratories Identifier:
First received: February 22, 2011
Last updated: September 27, 2012
Last verified: September 2012
A pilot study to evaluate the safety and efficacy of BLI801 vs. placebo in constipated adults.

Condition Intervention Phase
Constipation Drug: BLI801 Drug: Placebo Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Pilot Efficacy Evaluation of BLI801 Laxative in Constipated Adults

Resource links provided by NLM:

Further study details as provided by Braintree Laboratories:

Primary Outcome Measures:
  • percentage of patients experiencing a bowel movement within 3 hours of the first study medication dose [ Time Frame: 3 hours ]

Secondary Outcome Measures:
  • percentage of patients experiencing a complete/satisfactory bowel movement (BM) within 3 hours of first dose [ Time Frame: 3 hours ]
  • serum chemistry [ Time Frame: 7 days ]

Enrollment: 52
Study Start Date: January 2011
Primary Completion Date: May 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: BLI801 laxative
BLI801 laxative - oral solution
Drug: BLI801
BLI801 laxative - oral solution
Placebo Comparator: Placebo
BLI801 placebo - oral solution
Drug: Placebo
BLI801 placebo - oral solution


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Constipated, defined by ROME III definition
  • Subject has < 3 satisfactory BMs during the run-in period

Exclusion Criteria:

  • Subjects with known or suspected ileus, gastrointestinal obstruction, gastric retention, bowel perforation, toxic colitis, toxic megacolon
  • Subjects taking laxatives or prokinetic agents that refuse to discontinue these treatments.
  • Subjects who are allergic to any BLI801 component
  • Subjects taking narcotic analgesics or other medications known to cause constipation.
  • Subjects who, in the opinion of the Investigator, should not be included in the study for any reason, including inability to follow study procedures
  • Subjects who have participated in an investigational clinical, surgical, drug, or device study within the past 30 days
  • Subjects with an active history of drug or alcohol abuse
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01301781

United States, California
Advanced Clinical Research Institute
Anaheim, California, United States, 92801
United States, Florida
Jupiter Research
Jupiter, Florida, United States, 33458
United Medical Research
New Smyrna Beach, Florida, United States, 32168
United States, New York
Long Island GI Research Group
Great Neck, New York, United States, 11023
Sponsors and Collaborators
Braintree Laboratories
  More Information

Responsible Party: Braintree Laboratories Identifier: NCT01301781     History of Changes
Other Study ID Numbers: BLI801-201
Study First Received: February 22, 2011
Last Updated: September 27, 2012

Additional relevant MeSH terms:
Signs and Symptoms, Digestive
Signs and Symptoms
Pharmaceutical Solutions
Gastrointestinal Agents processed this record on August 16, 2017